[CYCC] Cyclacel Pharmaceuticals, Inc.

Overview

Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 3.95 Change: -0.05 (-1.25%)
Ext. hours: Change: 0 (0%)

chart CYCC

Refresh chart

Strongest Trends Summary For CYCC

CYCC is in the medium-term down -49% below S&P in 1 year. In the long-term down -72% below S&P in 2 years and down -100% below S&P in 10 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: Cyclacel Pharmaceuticals, Inc., a development-stage biopharmaceutical company, develops and commercializes mechanism-targeted drugs to treat human cancers and other serious diseases. The company?s oncology development programs include sapacitabine, an orally-available nucleoside analogue that interferes with DNA synthesis and repair by causing single-strand DNA breaks that could induce arrest of the cell division cycle at the G2/M checkpoint; and seliciclib, an orally-available 2nd generation CDK inhibitor that selectively inhibits a spectrum of enzyme targets comprising CDK2/E, CDK2/A, CDK7, and CDK9 that are central to the process of cell division and cell cycle control. Its other oncology development programs comprise CYC065, an orally-available 2nd generation CDK-2, -5, -9 inhibitor that helps in cancer cell growth, metastatic spread, and DNA damage repair; CYC140, an orally-available small molecule inhibitor of polo-like kinase 1; and Sapacitabine + Seliciclib, which is in Phase I trials for the treatmen

See how to gain 20% in 14 sec with TrendsInvesting

Fundamental Ratios
Shares Outstanding EPS EPS Growth - 4 Quarters2.06% EPS Growth - Q/Q2.33%
EPS Growth - Y/Y Sales Growth - 4 Quarters 43.82% Sales Growth - Q/Q107.29% P/E
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA-54.95% ROE-71.89% ROI
Current Ratio4.3 Quick Ratio Long Term Debt/Equity Debt Ratio0.3
Gross Margin Operating Margin-1206.76% Net Profit Margin-1050.27% Dividend Payout Ratio1.03%
Dividend Yield
Fundamental Data
Cash From Financing Activities10.38 M Cash From Investing Activities10 K Cash From Operating Activities-4.9 M Gross Profit
Net Profit-4.91 M Operating Profit-5.3 M Total Assets35.36 M Total Current Assets35.02 M
Total Current Liabilities8.14 M Total Debt Total Liabilities8.33 M Total Revenue510 K
Technical Data
High 52 week1.54 Low 52 week0.36 Last close0.37 Last change-5.13%
RSI42.11 Average true range0.03 Beta0.71 Volume60.16 K
Simple moving average 20 days-5.85% Simple moving average 50 days-13.35% Simple moving average 200 days-42.16%
Performance Data
Performance Week0% Performance Month-26% Performance Quart-32.73% Performance Half-50%
Performance Year-73.19% Performance Year-to-date-38.84% Volatility daily4.9% Volatility weekly10.96%
Volatility monthly22.46% Volatility yearly77.81% Relative Volume171.73% Average Volume71.56 K
New High New Low

News

2019-12-11 06:13:17 | Introducing Cyclacel Pharmaceuticals NASDAQ:CYCC, The Stock That Tanked 92%

2019-12-09 07:00:10 | Cyclacel’s CYC065 and Venetoclax Demonstrate Therapeutic Potential and Anticancer Activity in Acute Myeloid and Chronic Lymphocytic Leukemias

2019-11-16 15:08:38 | Edited Transcript of CYCC earnings conference call or presentation 13-Nov-19 9:30pm GMT

2019-11-13 16:05:00 | Cyclacel Pharmaceuticals Reports Third Quarter 2019 Financial Results

2019-11-07 07:00:00 | Cyclacel Pharmaceuticals to Release Third Quarter 2019 Financial Results

2019-11-06 09:00:00 | Cyclacel Pharmaceuticals Announces Multiple Clinical Abstracts Selected for Presentation at the ASH 2019 Annual Meeting

2019-10-12 09:44:20 | Here's Why We're Watching Cyclacel Pharmaceuticals's NASDAQ:CYCC Cash Burn Situation

2019-09-23 07:00:00 | Cyclacel Pharmaceuticals to Present at the Ladenburg Thalmann 2019 Healthcare Conference

2019-09-09 07:00:00 | Cyclacel Pharmaceuticals Announces First Patient Treated With Oral CYC065 in a Phase 1 Study in Patients With Advanced Solid Tumors

2019-09-04 07:00:00 | Cyclacel Pharmaceuticals to Present at the 21st Annual H.C. Wainwright Global Investment Conference   

2019-08-28 12:34:50 | Is Cyclacel Pharmaceuticals, Inc.'s NASDAQ:CYCC CEO Paid At A Competitive Rate?

2019-08-14 05:59:38 | Edited Transcript of CYCC earnings conference call or presentation 13-Aug-19 8:30pm GMT

2019-08-13 16:05:00 | Cyclacel Pharmaceuticals Reports Second Quarter 2019 Financial Results

2019-08-13 07:25:15 | The Daily Biotech Pulse: Jazz Goes Shopping, Portola Offering, Novelion Delays Quarterly Results

2019-08-11 15:46:20 | The Week Ahead In Biotech: Vanda Awaits FDA Decision, BioVie Plans IPO

2019-08-07 07:00:00 | Cyclacel Pharmaceuticals to Release Second Quarter 2019 Financial Results

2019-07-22 07:00:00 | Cyclacel Pharmaceuticals Announces First Patient Treated in a Phase 1/2 Study of Sapacitabine and Venetoclax in Relapsed or Refractory AML or MDS Patients

2019-06-26 14:59:42 | Some Cyclacel Pharmaceuticals NASDAQ:CYCC Shareholders Have Copped A 99% Share Price Wipe Out

2019-05-24 12:50:18 | A Look At Benzinga Pro's Most-Searched Tickers For May 24

2019-05-14 22:22:40 | Edited Transcript of CYCC earnings conference call or presentation 14-May-19 8:30pm GMT

2019-05-14 16:05:00 | Cyclacel Pharmaceuticals Reports First Quarter 2019 Financial Results

2019-05-08 07:00:00 | Cyclacel Pharmaceuticals to Release First Quarter 2019 Financial Results

2019-04-29 09:55:51 | Could Cyclacel Pharmaceuticals, Inc.'s NASDAQ:CYCC Investor Composition Influence The Stock Price?

2019-04-01 07:00:00 | Cyclacel Announces Presentation of Phase 1 Data of Sapacitabine Regimen in Patients With BRCA Mutant Breast Cancer at AACR 2019

2019-03-28 08:16:49 | Edited Transcript of CYCC earnings conference call or presentation 27-Mar-19 8:30pm GMT

2019-03-27 16:05:00 | Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results

2019-03-27 07:52:54 | The Daily Biotech Pulse: FDA Nod For Novartis, Jazz Positive Late-Stage Data For Sleep Disorder Drug, Genfit IPO

2019-03-26 12:46:27 | Cyclacel Drops After Study Supporting Cancer Drug's Mechanism Of Action

2019-03-26 08:30:00 | Cyclacel Provides Clinical Development Update and Growth Drivers for 2019 in New SNNLive Video Interview on StockNewsNow.com

2019-03-25 07:00:00 | Publication Identifies Cyclin E as Key Resistance Pathway to Breast Cancer Treated by CDK4/6 Inhibitors and Thereby Amenable to Treatment by CYC065 CDK2/9 Inhibitor

2019-03-20 07:00:00 | Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2018 Financial Results

2019-03-13 07:00:00 | Cyclacel to Participate in 31st Annual ROTH Conference March 18-19

2019-03-05 07:00:00 | Cyclacel Announces Abstracts Selected for Presentation at the American Association for Cancer Research Annual Meeting 2019

2019-02-05 07:00:00 | Cyclacel Pharmaceuticals to Present at the 2019 BIO CEO & Investor Conference

2019-01-24 07:25:00 | New Research: Key Drivers of Growth for Square, American International Group, PolyOne, Sonoco Products, Enviva Partners, LP, and Cyclacel Pharmaceuticals — Factors of Influence, Major Initiatives and Sustained Production

2019-01-07 07:00:00 | Cyclacel Pharmaceuticals Reviews 2018 Achievements and Announces Key Business Objectives for 2019

2018-12-27 07:00:00 | Cyclacel Pharmaceuticals to Present at Biotech Showcase™ 2019 in San Francisco

2018-12-25 14:25:20 | Does Cyclacel Pharmaceuticals, Inc.’s NASDAQ:CYCC CEO Pay Reflect Performance?

2018-12-04 07:35:00 | Consolidated Research: 2018 Summary Expectations for Xencor, Cyclacel Pharmaceuticals, Amicus Therapeutics, Take-Two Interactive Software, CSG Systems International, and Vonage — Fundamental Analysis, Key Performance Indications

2018-11-13 07:54:38 | The Daily Biotech Pulse: Viking's Fatty Liver And Cholesterol Drug, Cyclacel Loss Narrows, Eton's Debut

2018-11-13 07:26:43 | Edited Transcript of CYCC earnings conference call or presentation 12-Nov-18 9:30pm GMT

2018-11-12 16:05:00 | Cyclacel Pharmaceuticals Reports Third Quarter 2018 Financial Results

2018-11-06 07:00:00 | Cyclacel Pharmaceuticals to Release Third Quarter 2018 Financial Results

2018-10-25 08:30:00 | Report: Exploring Fundamental Drivers Behind Invitae, Aerie Pharmaceuticals, Gevo, Global Medical REIT, Cyclacel Pharmaceuticals, and Toll Brothers — New Horizons, Emerging Trends, and Upcoming Developments

2018-10-23 07:00:00 | Cyclacel Pharmaceuticals to Present at the Dawson James Small Cap Growth Conference

2018-10-04 07:00:00 | Cyclacel Pharmaceuticals and MD Anderson Cancer Center Announce Strategic Alliance to Study Novel Cyclacel Medicines in Hematological Malignancies

2018-09-26 07:00:00 | Cyclacel Pharmaceuticals to Present at the Ladenburg Thalmann 2018 Healthcare Conference

2018-09-20 13:01:51 | What does Cyclacel Pharmaceuticals Inc’s NASDAQ:CYCC Balance Sheet Tell Us About Its Future?

2018-09-12 07:00:00 | Cyclacel Pharmaceuticals Appoints Robert J. Spiegel, M.D. to Board of Directors

2018-09-10 07:00:00 | Cyclacel Pharmaceuticals Announces Initiation of Phase 1b/2 Clinical Trial of Sapacitabine With Olaparib in BRCA Mutant Breast Cancer